Chlamydia Trachomatis Clinical Trial
Official title:
Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial
Urogenital Chlamydia trachomatis infection is the most common bacterial sexually transmitted infection in Norway. Urogential C.trachomatis infection can easily be treated with antibiotics. However, left untreated it is a major cause of pelvic inflammatory disease (PID) that can lead to complications such as infertility, ectopic pregnancy and chronic pelvic pain in women. Most infections are asymptomatic and many do not seek the doctor for testing. Therefore cases remain undetected and untreated.We want to determine the efficacy and feasibility of screening for urogenital C. trachomatis infection with home sampling (intervention) compared to the current strategy of conventional sampling at the doctor's office (control) in identifying men and women aged 18-25 years with urogenital C.trachomatis infection (Part A). We also want to identify factors influencing the acceptability of home sampling for C.trachomatis infections (Part B)and determine factors associated with C.trachomatis infections (Part C).
Study design The different objectives will be addressed through a complex design with
several sub-studies.
Part A is a randomised control trial where we compare the intervention group who will be
offered home-sampling and recieve a package by mail (containing information on urogenital
C.trachomatis infections, sampling eqiupment for urine tests and a questionnaire) with a
control group who will continue with todays system of conventional sampling at the doctores
office (no intervention). The study population are all men and women between 18-25 years of
age in Rogaland County in Norway. The population register will be used to randomly assigne
to either the intervention group or the control group.The intervention group will be asked
to take a urine sample and send this by mail to the laboratory for analysis within three
months after the invitation, and to fill out and return a questionnaire. For the ones in the
control group all samples(urethral or cervical swabs or urine samples)taken within the same
three months will be sendt to the same laboratory. In this part of the study we will measure
the yield ratio for the tested, diagnosed and treated in the two groupsafter the study
period of three months. All samples either obtained at home or at the physician's office,
will be analyzed by BDProbeTec ET Chlamydia Amplified DNA assay. This is a well documented
Nucleid Acid amplification method. Samples will be analysed according to manufactures
instructions. Data on number of tested and diagnosed in the two groups will be collected
from Stvanger University Hospital. Data on number of treated will be collected from the
Norwegain Prescription Database by merging the study dataset with their datafiles. This way
we will recive information on who has received treatment for C.rachomatis within one month
after after a positive C.trachomatis test.
In Part B a case-cohort from the intervention group (Part A) consisting of a random
selection of respondents and non-respondents will be used to determine the feasibility of
home sampling as a screening strategy by measuring the risk (OR) related to different
factors that determined response. Data are collected through selfadminitered questionnaires.
Part C is a cross sectional study consisting of all respondents in the intervention group.
In this part we will measure Prevalence Ratio(PR) of urogential C.trachomatis infections
associated with different factors by comparing C.trachomatis positive and C.trachomatis
negative in the intervention group.
Part D is an economic study which will be addressed in a separate protocol.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676816 -
Self Sampling for Rapid Turnaround Testing in the Emergency Department
|
N/A | |
Completed |
NCT00213018 -
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
|
Phase 2 | |
Completed |
NCT00827970 -
Randomized Population-Based Study on Chlamydia Trachomatis Screening
|
N/A | |
Withdrawn |
NCT01358799 -
Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System
|
N/A | |
Completed |
NCT01733069 -
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
|
N/A | |
Completed |
NCT00978848 -
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
|
N/A | |
Completed |
NCT02391233 -
Multimedia WORTH With Black Drug-Involved Women on Probation
|
N/A | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT03071510 -
Evaluation of the Atlas Genetics io® CTNG System
|
||
Recruiting |
NCT04446611 -
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes
|
N/A | |
Completed |
NCT01329588 -
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
|
Phase 4 | |
Not yet recruiting |
NCT06216964 -
Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study
|
N/A | |
Terminated |
NCT02795975 -
Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples
|
N/A | |
Completed |
NCT00207454 -
Optimizing Strategies to Improve STD Partner Services
|
Phase 1 | |
Completed |
NCT00213057 -
Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand
|
Phase 1 | |
Completed |
NCT00177437 -
Home Screening for Chlamydia Surveillance
|
Phase 3 | |
Completed |
NCT02787109 -
Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years
|
Phase 1 | |
Completed |
NCT01665690 -
Washington State Community Expedited Partner Treatment (EPT) Trial
|
Phase 4 | |
Completed |
NCT02128620 -
A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 |